nodes	percent_of_prediction	percent_of_DWPC	metapath
Clodronate—SLC25A6—Influenza Virus Induced Apoptosis—TGFB1—systemic scleroderma	0.0446	0.266	CbGpPWpGaD
Clodronate—SLC25A6—connective tissue—systemic scleroderma	0.0236	0.0839	CbGeAlD
Clodronate—PTGS2—skeletal joint—systemic scleroderma	0.0232	0.0822	CbGeAlD
Clodronate—SLC25A6—Host Interactions with Influenza Factors—TGFB1—systemic scleroderma	0.0214	0.128	CbGpPWpGaD
Clodronate—SLC25A6—skin of body—systemic scleroderma	0.0214	0.0758	CbGeAlD
Clodronate—SLC25A5—connective tissue—systemic scleroderma	0.0206	0.073	CbGeAlD
Clodronate—SLC25A5—smooth muscle tissue—systemic scleroderma	0.0188	0.0668	CbGeAlD
Clodronate—SLC25A5—skin of body—systemic scleroderma	0.0186	0.0659	CbGeAlD
Clodronate—SLC25A6—digestive system—systemic scleroderma	0.0171	0.0606	CbGeAlD
Clodronate—SLC25A5—digestive system—systemic scleroderma	0.0149	0.0527	CbGeAlD
Clodronate—SLC25A6—lung—systemic scleroderma	0.0143	0.0506	CbGeAlD
Clodronate—SLC25A5—tendon—systemic scleroderma	0.0141	0.0502	CbGeAlD
Clodronate—SLC25A4—digestive system—systemic scleroderma	0.0139	0.0494	CbGeAlD
Clodronate—SLC25A4—tendon—systemic scleroderma	0.0132	0.047	CbGeAlD
Clodronate—SLC25A5—lung—systemic scleroderma	0.0124	0.044	CbGeAlD
Clodronate—SLC25A4—lung—systemic scleroderma	0.0116	0.0413	CbGeAlD
Clodronate—PTGS2—artery—systemic scleroderma	0.0097	0.0344	CbGeAlD
Clodronate—PTGS2—Fluocinonide—Mometasone—systemic scleroderma	0.00822	0.624	CbGdCrCtD
Clodronate—PTGS2—endothelium—systemic scleroderma	0.00819	0.0291	CbGeAlD
Clodronate—SLC25A5—Host Interactions of HIV factors—CD247—systemic scleroderma	0.00806	0.048	CbGpPWpGaD
Clodronate—PTGS2—blood vessel—systemic scleroderma	0.00755	0.0268	CbGeAlD
Clodronate—SLC25A6—Host Interactions of HIV factors—CD247—systemic scleroderma	0.00675	0.0402	CbGpPWpGaD
Clodronate—SLC25A4—Host Interactions of HIV factors—CD247—systemic scleroderma	0.00527	0.0314	CbGpPWpGaD
Clodronate—SLC25A5—HIV Infection—CD247—systemic scleroderma	0.00523	0.0312	CbGpPWpGaD
Clodronate—Hepatocellular injury—Captopril—systemic scleroderma	0.00501	0.00932	CcSEcCtD
Clodronate—PTGS2—Fluticasone Propionate—Mometasone—systemic scleroderma	0.00496	0.376	CbGdCrCtD
Clodronate—Neoplasm malignant—Mycophenolic acid—systemic scleroderma	0.00461	0.00858	CcSEcCtD
Clodronate—Hypercalcaemia—Mycophenolate mofetil—systemic scleroderma	0.00447	0.00832	CcSEcCtD
Clodronate—SLC25A6—HIV Infection—CD247—systemic scleroderma	0.00439	0.0261	CbGpPWpGaD
Clodronate—Hepatocellular injury—Azathioprine—systemic scleroderma	0.00437	0.00813	CcSEcCtD
Clodronate—Hypocalcaemia—Mycophenolic acid—systemic scleroderma	0.0043	0.008	CcSEcCtD
Clodronate—Oliguria—Mycophenolic acid—systemic scleroderma	0.00427	0.00795	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.00419	0.0249	CbGpPWpGaD
Clodronate—Creatinine increased—Mycophenolic acid—systemic scleroderma	0.00413	0.0077	CcSEcCtD
Clodronate—Hepatocellular injury—Leflunomide—systemic scleroderma	0.00413	0.00768	CcSEcCtD
Clodronate—Bronchospasm—Pentoxifylline—systemic scleroderma	0.00408	0.00759	CcSEcCtD
Clodronate—Proteinuria—Lisinopril—systemic scleroderma	0.00403	0.00751	CcSEcCtD
Clodronate—Protein urine present—Lisinopril—systemic scleroderma	0.00398	0.00741	CcSEcCtD
Clodronate—Hepatocellular injury—Mycophenolic acid—systemic scleroderma	0.00394	0.00733	CcSEcCtD
Clodronate—Renal failure acute—Captopril—systemic scleroderma	0.00394	0.00733	CcSEcCtD
Clodronate—PTGS2—connective tissue—systemic scleroderma	0.00387	0.0137	CbGeAlD
Clodronate—Oliguria—Lisinopril—systemic scleroderma	0.00385	0.00716	CcSEcCtD
Clodronate—Wheezing—Mycophenolic acid—systemic scleroderma	0.00382	0.00711	CcSEcCtD
Clodronate—Creatinine increased—Lisinopril—systemic scleroderma	0.00372	0.00693	CcSEcCtD
Clodronate—Hepatic function abnormal—Azathioprine—systemic scleroderma	0.00363	0.00675	CcSEcCtD
Clodronate—PTGS2—smooth muscle tissue—systemic scleroderma	0.00354	0.0126	CbGeAlD
Clodronate—Bronchospasm—Mometasone—systemic scleroderma	0.00352	0.00655	CcSEcCtD
Clodronate—PTGS2—skin of body—systemic scleroderma	0.0035	0.0124	CbGeAlD
Clodronate—Wheezing—Lisinopril—systemic scleroderma	0.00344	0.00641	CcSEcCtD
Clodronate—SLC25A4—HIV Infection—CD247—systemic scleroderma	0.00342	0.0204	CbGpPWpGaD
Clodronate—Hypocalcaemia—Mycophenolate mofetil—systemic scleroderma	0.00339	0.00632	CcSEcCtD
Clodronate—Oliguria—Mycophenolate mofetil—systemic scleroderma	0.00337	0.00627	CcSEcCtD
Clodronate—Creatinine increased—Mycophenolate mofetil—systemic scleroderma	0.00326	0.00607	CcSEcCtD
Clodronate—PTGS2—Spinal Cord Injury—AIF1—systemic scleroderma	0.00316	0.0188	CbGpPWpGaD
Clodronate—Hepatocellular injury—Mycophenolate mofetil—systemic scleroderma	0.00311	0.00578	CcSEcCtD
Clodronate—Renal failure acute—Mycophenolic acid—systemic scleroderma	0.00309	0.00576	CcSEcCtD
Clodronate—Bronchospasm—Captopril—systemic scleroderma	0.00309	0.00575	CcSEcCtD
Clodronate—Renal impairment—Mycophenolic acid—systemic scleroderma	0.003	0.00559	CcSEcCtD
Clodronate—Hepatic function abnormal—Lisinopril—systemic scleroderma	0.00294	0.00548	CcSEcCtD
Clodronate—Cardiac failure—Mycophenolic acid—systemic scleroderma	0.00293	0.00545	CcSEcCtD
Clodronate—Pharyngitis—Mometasone—systemic scleroderma	0.00284	0.00529	CcSEcCtD
Clodronate—PTGS2—digestive system—systemic scleroderma	0.0028	0.00993	CbGeAlD
Clodronate—Renal failure acute—Lisinopril—systemic scleroderma	0.00279	0.00519	CcSEcCtD
Clodronate—Renal failure—Captopril—systemic scleroderma	0.00275	0.00512	CcSEcCtD
Clodronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—systemic scleroderma	0.00272	0.0162	CbGpPWpGaD
Clodronate—Renal impairment—Lisinopril—systemic scleroderma	0.0027	0.00503	CcSEcCtD
Clodronate—Blood creatinine increased—Mycophenolic acid—systemic scleroderma	0.00268	0.00498	CcSEcCtD
Clodronate—Anaemia—Pentoxifylline—systemic scleroderma	0.00267	0.00497	CcSEcCtD
Clodronate—PTGS2—tendon—systemic scleroderma	0.00266	0.00945	CbGeAlD
Clodronate—Dehydration—Mycophenolic acid—systemic scleroderma	0.00266	0.00495	CcSEcCtD
Clodronate—Angioedema—Pentoxifylline—systemic scleroderma	0.00264	0.00491	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.00263	0.0157	CbGpPWpGaD
Clodronate—Abdominal pain upper—Mycophenolic acid—systemic scleroderma	0.00261	0.00486	CcSEcCtD
Clodronate—Liver disorder—Methotrexate—systemic scleroderma	0.00258	0.0048	CcSEcCtD
Clodronate—Mediastinal disorder—Mometasone—systemic scleroderma	0.00258	0.0048	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Mycophenolic acid—systemic scleroderma	0.00252	0.00469	CcSEcCtD
Clodronate—Pharyngitis—Captopril—systemic scleroderma	0.00249	0.00464	CcSEcCtD
Clodronate—Dysphagia—Mycophenolic acid—systemic scleroderma	0.00247	0.0046	CcSEcCtD
Clodronate—Pneumonia—Azathioprine—systemic scleroderma	0.00246	0.00458	CcSEcCtD
Clodronate—Renal failure acute—Mycophenolate mofetil—systemic scleroderma	0.00244	0.00455	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—systemic scleroderma	0.00244	0.00454	CcSEcCtD
Clodronate—Blood creatinine increased—Lisinopril—systemic scleroderma	0.00241	0.00449	CcSEcCtD
Clodronate—Dehydration—Lisinopril—systemic scleroderma	0.00239	0.00445	CcSEcCtD
Clodronate—Renal impairment—Mycophenolate mofetil—systemic scleroderma	0.00237	0.00441	CcSEcCtD
Clodronate—Infection—Pentoxifylline—systemic scleroderma	0.00234	0.00436	CcSEcCtD
Clodronate—PTGS2—lung—systemic scleroderma	0.00234	0.00829	CbGeAlD
Clodronate—Pneumonia—Leflunomide—systemic scleroderma	0.00232	0.00432	CcSEcCtD
Clodronate—Cardiac failure—Mycophenolate mofetil—systemic scleroderma	0.00231	0.0043	CcSEcCtD
Clodronate—Skin disorder—Pentoxifylline—systemic scleroderma	0.00229	0.00426	CcSEcCtD
Clodronate—Angioedema—Mometasone—systemic scleroderma	0.00228	0.00424	CcSEcCtD
Clodronate—Renal failure—Leflunomide—systemic scleroderma	0.00227	0.00422	CcSEcCtD
Clodronate—Anorexia—Pentoxifylline—systemic scleroderma	0.00225	0.00418	CcSEcCtD
Clodronate—Pneumonia—Mycophenolic acid—systemic scleroderma	0.00221	0.00412	CcSEcCtD
Clodronate—Bronchospasm—Lisinopril—systemic scleroderma	0.00219	0.00407	CcSEcCtD
Clodronate—Renal failure—Mycophenolic acid—systemic scleroderma	0.00216	0.00403	CcSEcCtD
Clodronate—Blood creatinine increased—Mycophenolate mofetil—systemic scleroderma	0.00211	0.00393	CcSEcCtD
Clodronate—Dyspnoea—Pentoxifylline—systemic scleroderma	0.0021	0.00391	CcSEcCtD
Clodronate—Dehydration—Mycophenolate mofetil—systemic scleroderma	0.0021	0.0039	CcSEcCtD
Clodronate—Dyspepsia—Pentoxifylline—systemic scleroderma	0.00207	0.00386	CcSEcCtD
Clodronate—Pharyngitis—Leflunomide—systemic scleroderma	0.00206	0.00383	CcSEcCtD
Clodronate—Decreased appetite—Pentoxifylline—systemic scleroderma	0.00205	0.00381	CcSEcCtD
Clodronate—Urinary tract disorder—Leflunomide—systemic scleroderma	0.00205	0.00381	CcSEcCtD
Clodronate—Connective tissue disorder—Leflunomide—systemic scleroderma	0.00204	0.00379	CcSEcCtD
Clodronate—Urethral disorder—Leflunomide—systemic scleroderma	0.00203	0.00378	CcSEcCtD
Clodronate—Anaemia—Captopril—systemic scleroderma	0.00202	0.00376	CcSEcCtD
Clodronate—Infection—Mometasone—systemic scleroderma	0.00202	0.00376	CcSEcCtD
Clodronate—Extravasation—Methotrexate—systemic scleroderma	0.00202	0.00375	CcSEcCtD
Clodronate—Proteinuria—Methotrexate—systemic scleroderma	0.002	0.00373	CcSEcCtD
Clodronate—Angioedema—Captopril—systemic scleroderma	0.002	0.00372	CcSEcCtD
Clodronate—Pneumonia—Lisinopril—systemic scleroderma	0.00199	0.00371	CcSEcCtD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—systemic scleroderma	0.00199	0.0119	CbGpPWpGaD
Clodronate—Alanine aminotransferase increased—Mycophenolate mofetil—systemic scleroderma	0.00199	0.0037	CcSEcCtD
Clodronate—Mediastinal disorder—Azathioprine—systemic scleroderma	0.00198	0.00368	CcSEcCtD
Clodronate—Protein urine present—Methotrexate—systemic scleroderma	0.00197	0.00368	CcSEcCtD
Clodronate—Pharyngitis—Mycophenolic acid—systemic scleroderma	0.00196	0.00365	CcSEcCtD
Clodronate—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.00196	0.0117	CbGpPWpGaD
Clodronate—Urinary tract disorder—Mycophenolic acid—systemic scleroderma	0.00195	0.00363	CcSEcCtD
Clodronate—Renal failure—Lisinopril—systemic scleroderma	0.00195	0.00363	CcSEcCtD
Clodronate—Dysphagia—Mycophenolate mofetil—systemic scleroderma	0.00195	0.00363	CcSEcCtD
Clodronate—Connective tissue disorder—Mycophenolic acid—systemic scleroderma	0.00194	0.00362	CcSEcCtD
Clodronate—Anorexia—Mometasone—systemic scleroderma	0.00194	0.00361	CcSEcCtD
Clodronate—Urethral disorder—Mycophenolic acid—systemic scleroderma	0.00194	0.00361	CcSEcCtD
Clodronate—SLC25A5—Disease—SMAD7—systemic scleroderma	0.00194	0.0115	CbGpPWpGaD
Clodronate—Oliguria—Methotrexate—systemic scleroderma	0.00191	0.00355	CcSEcCtD
Clodronate—Urticaria—Pentoxifylline—systemic scleroderma	0.00187	0.00348	CcSEcCtD
Clodronate—Mediastinal disorder—Leflunomide—systemic scleroderma	0.00187	0.00348	CcSEcCtD
Clodronate—Abdominal pain—Pentoxifylline—systemic scleroderma	0.00186	0.00347	CcSEcCtD
Clodronate—Dyspnoea—Mometasone—systemic scleroderma	0.00181	0.00337	CcSEcCtD
Clodronate—Dyspepsia—Mometasone—systemic scleroderma	0.00179	0.00333	CcSEcCtD
Clodronate—Mediastinal disorder—Mycophenolic acid—systemic scleroderma	0.00178	0.00332	CcSEcCtD
Clodronate—SLC25A5—Disease—TGFBI—systemic scleroderma	0.00177	0.0106	CbGpPWpGaD
Clodronate—Decreased appetite—Mometasone—systemic scleroderma	0.00177	0.00329	CcSEcCtD
Clodronate—Pharyngitis—Lisinopril—systemic scleroderma	0.00177	0.00329	CcSEcCtD
Clodronate—Anaemia—Azathioprine—systemic scleroderma	0.00177	0.00329	CcSEcCtD
Clodronate—Urinary tract disorder—Lisinopril—systemic scleroderma	0.00176	0.00327	CcSEcCtD
Clodronate—Pneumonia—Mycophenolate mofetil—systemic scleroderma	0.00175	0.00325	CcSEcCtD
Clodronate—Urethral disorder—Lisinopril—systemic scleroderma	0.00174	0.00325	CcSEcCtD
Clodronate—Renal failure—Mycophenolate mofetil—systemic scleroderma	0.00171	0.00318	CcSEcCtD
Clodronate—Anorexia—Captopril—systemic scleroderma	0.0017	0.00317	CcSEcCtD
Clodronate—Pruritus—Pentoxifylline—systemic scleroderma	0.00167	0.0031	CcSEcCtD
Clodronate—Anaemia—Leflunomide—systemic scleroderma	0.00167	0.0031	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—systemic scleroderma	0.00165	0.00986	CbGpPWpGaD
Clodronate—Angioedema—Leflunomide—systemic scleroderma	0.00165	0.00307	CcSEcCtD
Clodronate—SLC25A6—Disease—SMAD7—systemic scleroderma	0.00162	0.00967	CbGpPWpGaD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00161	0.00301	CcSEcCtD
Clodronate—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00161	0.003	CcSEcCtD
Clodronate—Abdominal pain—Mometasone—systemic scleroderma	0.00161	0.00299	CcSEcCtD
Clodronate—Mediastinal disorder—Lisinopril—systemic scleroderma	0.0016	0.00299	CcSEcCtD
Clodronate—Dyspnoea—Captopril—systemic scleroderma	0.00159	0.00296	CcSEcCtD
Clodronate—Anaemia—Mycophenolic acid—systemic scleroderma	0.00159	0.00296	CcSEcCtD
Clodronate—PTGS2—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.00159	0.00946	CbGpPWpGaD
Clodronate—Dyspepsia—Captopril—systemic scleroderma	0.00157	0.00293	CcSEcCtD
Clodronate—Cardiac failure—Prednisone—systemic scleroderma	0.00157	0.00291	CcSEcCtD
Clodronate—Decreased appetite—Captopril—systemic scleroderma	0.00155	0.00289	CcSEcCtD
Clodronate—Infection—Azathioprine—systemic scleroderma	0.00155	0.00288	CcSEcCtD
Clodronate—Pharyngitis—Mycophenolate mofetil—systemic scleroderma	0.00155	0.00288	CcSEcCtD
Clodronate—PTGS2—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.00154	0.00919	CbGpPWpGaD
Clodronate—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.00154	0.00287	CcSEcCtD
Clodronate—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.00153	0.00285	CcSEcCtD
Clodronate—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.00153	0.00285	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.00152	0.00284	CcSEcCtD
Clodronate—Skin disorder—Azathioprine—systemic scleroderma	0.00151	0.00282	CcSEcCtD
Clodronate—Vomiting—Pentoxifylline—systemic scleroderma	0.0015	0.00279	CcSEcCtD
Clodronate—Rash—Pentoxifylline—systemic scleroderma	0.00149	0.00277	CcSEcCtD
Clodronate—Dermatitis—Pentoxifylline—systemic scleroderma	0.00148	0.00276	CcSEcCtD
Clodronate—SLC25A6—Disease—TGFBI—systemic scleroderma	0.00148	0.00884	CbGpPWpGaD
Clodronate—SLC25A6—Influenza Infection—TGFB1—systemic scleroderma	0.00148	0.00883	CbGpPWpGaD
Clodronate—Infection—Leflunomide—systemic scleroderma	0.00146	0.00272	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.00145	0.00271	CcSEcCtD
Clodronate—Pruritus—Mometasone—systemic scleroderma	0.00144	0.00268	CcSEcCtD
Clodronate—Anaemia—Lisinopril—systemic scleroderma	0.00143	0.00267	CcSEcCtD
Clodronate—Skin disorder—Leflunomide—systemic scleroderma	0.00143	0.00266	CcSEcCtD
Clodronate—Angioedema—Lisinopril—systemic scleroderma	0.00142	0.00264	CcSEcCtD
Clodronate—SLC25A5—Disease—HSPG2—systemic scleroderma	0.00141	0.00842	CbGpPWpGaD
Clodronate—Abdominal pain—Captopril—systemic scleroderma	0.00141	0.00263	CcSEcCtD
Clodronate—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00141	0.00262	CcSEcCtD
Clodronate—Anorexia—Leflunomide—systemic scleroderma	0.0014	0.00261	CcSEcCtD
Clodronate—Nausea—Pentoxifylline—systemic scleroderma	0.0014	0.00261	CcSEcCtD
Clodronate—Infection—Mycophenolic acid—systemic scleroderma	0.00139	0.0026	CcSEcCtD
Clodronate—Diarrhoea—Mometasone—systemic scleroderma	0.00139	0.00259	CcSEcCtD
Clodronate—Renal failure acute—Methotrexate—systemic scleroderma	0.00138	0.00258	CcSEcCtD
Clodronate—PTGS2—Spinal Cord Injury—SELP—systemic scleroderma	0.00137	0.00819	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.00137	0.00819	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CSK—systemic scleroderma	0.00136	0.00813	CbGpPWpGaD
Clodronate—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00136	0.00254	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—ACE—systemic scleroderma	0.00136	0.00813	CbGpPWpGaD
Clodronate—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.00135	0.00251	CcSEcCtD
Clodronate—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00135	0.0025	CcSEcCtD
Clodronate—Anorexia—Mycophenolic acid—systemic scleroderma	0.00134	0.00249	CcSEcCtD
Clodronate—Dyspnoea—Leflunomide—systemic scleroderma	0.00131	0.00244	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00131	0.00244	CcSEcCtD
Clodronate—Dyspepsia—Leflunomide—systemic scleroderma	0.0013	0.00241	CcSEcCtD
Clodronate—Vomiting—Mometasone—systemic scleroderma	0.00129	0.00241	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—systemic scleroderma	0.00129	0.00767	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CD247—systemic scleroderma	0.00128	0.00764	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—RHOB—systemic scleroderma	0.00128	0.00764	CbGpPWpGaD
Clodronate—Rash—Mometasone—systemic scleroderma	0.00128	0.00239	CcSEcCtD
Clodronate—Dermatitis—Mometasone—systemic scleroderma	0.00128	0.00238	CcSEcCtD
Clodronate—Decreased appetite—Leflunomide—systemic scleroderma	0.00128	0.00238	CcSEcCtD
Clodronate—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00127	0.00237	CcSEcCtD
Clodronate—SLC25A4—Disease—SMAD7—systemic scleroderma	0.00127	0.00755	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.00127	0.00754	CbGpPWpGaD
Clodronate—Pruritus—Captopril—systemic scleroderma	0.00126	0.00235	CcSEcCtD
Clodronate—Infection—Lisinopril—systemic scleroderma	0.00126	0.00234	CcSEcCtD
Clodronate—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.00125	0.00234	CcSEcCtD
Clodronate—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00125	0.00233	CcSEcCtD
Clodronate—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.00124	0.00231	CcSEcCtD
Clodronate—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00124	0.0023	CcSEcCtD
Clodronate—Abdominal pain—Azathioprine—systemic scleroderma	0.00123	0.00229	CcSEcCtD
Clodronate—Skin disorder—Lisinopril—systemic scleroderma	0.00123	0.00229	CcSEcCtD
Clodronate—Diarrhoea—Captopril—systemic scleroderma	0.00122	0.00227	CcSEcCtD
Clodronate—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00122	0.00227	CcSEcCtD
Clodronate—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00121	0.00226	CcSEcCtD
Clodronate—Nausea—Mometasone—systemic scleroderma	0.00121	0.00225	CcSEcCtD
Clodronate—Anorexia—Lisinopril—systemic scleroderma	0.00121	0.00224	CcSEcCtD
Clodronate—SLC25A6—Disease—HSPG2—systemic scleroderma	0.00118	0.00705	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—HSPG2—systemic scleroderma	0.00118	0.00705	CbGpPWpGaD
Clodronate—Urticaria—Leflunomide—systemic scleroderma	0.00117	0.00218	CcSEcCtD
Clodronate—Abdominal pain—Leflunomide—systemic scleroderma	0.00116	0.00217	CcSEcCtD
Clodronate—SLC25A4—Disease—TGFBI—systemic scleroderma	0.00116	0.0069	CbGpPWpGaD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00214	CcSEcCtD
Clodronate—SLC25A6—Disease—CSK—systemic scleroderma	0.00114	0.00681	CbGpPWpGaD
Clodronate—Vomiting—Captopril—systemic scleroderma	0.00114	0.00211	CcSEcCtD
Clodronate—Dyspnoea—Lisinopril—systemic scleroderma	0.00113	0.0021	CcSEcCtD
Clodronate—Rash—Captopril—systemic scleroderma	0.00113	0.0021	CcSEcCtD
Clodronate—Dermatitis—Captopril—systemic scleroderma	0.00112	0.00209	CcSEcCtD
Clodronate—Dyspepsia—Lisinopril—systemic scleroderma	0.00111	0.00207	CcSEcCtD
Clodronate—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00111	0.00207	CcSEcCtD
Clodronate—Infection—Mycophenolate mofetil—systemic scleroderma	0.0011	0.00205	CcSEcCtD
Clodronate—Decreased appetite—Lisinopril—systemic scleroderma	0.0011	0.00205	CcSEcCtD
Clodronate—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00109	0.00203	CcSEcCtD
Clodronate—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00108	0.002	CcSEcCtD
Clodronate—SLC25A6—Disease—CD247—systemic scleroderma	0.00107	0.00641	CbGpPWpGaD
Clodronate—Diarrhoea—Azathioprine—systemic scleroderma	0.00107	0.00198	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—ACE—systemic scleroderma	0.00106	0.00634	CbGpPWpGaD
Clodronate—Nausea—Captopril—systemic scleroderma	0.00106	0.00197	CcSEcCtD
Clodronate—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00197	CcSEcCtD
Clodronate—Pruritus—Leflunomide—systemic scleroderma	0.00104	0.00194	CcSEcCtD
Clodronate—Connective tissue disorder—Prednisone—systemic scleroderma	0.00104	0.00193	CcSEcCtD
Clodronate—Diarrhoea—Leflunomide—systemic scleroderma	0.00101	0.00187	CcSEcCtD
Clodronate—Urticaria—Lisinopril—systemic scleroderma	0.001	0.00187	CcSEcCtD
Clodronate—Abdominal pain—Lisinopril—systemic scleroderma	0.001	0.00186	CcSEcCtD
Clodronate—Pruritus—Mycophenolic acid—systemic scleroderma	0.000993	0.00185	CcSEcCtD
Clodronate—SLC25A6—Metabolism—HSPG2—systemic scleroderma	0.000991	0.00591	CbGpPWpGaD
Clodronate—Vomiting—Azathioprine—systemic scleroderma	0.000991	0.00184	CcSEcCtD
Clodronate—Pneumonia—Methotrexate—systemic scleroderma	0.00099	0.00184	CcSEcCtD
Clodronate—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000988	0.00184	CcSEcCtD
Clodronate—Rash—Azathioprine—systemic scleroderma	0.000983	0.00183	CcSEcCtD
Clodronate—Dermatitis—Azathioprine—systemic scleroderma	0.000982	0.00183	CcSEcCtD
Clodronate—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000975	0.00182	CcSEcCtD
Clodronate—Renal failure—Methotrexate—systemic scleroderma	0.000967	0.0018	CcSEcCtD
Clodronate—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000963	0.00179	CcSEcCtD
Clodronate—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000961	0.00179	CcSEcCtD
Clodronate—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000957	0.00178	CcSEcCtD
Clodronate—Vomiting—Leflunomide—systemic scleroderma	0.000936	0.00174	CcSEcCtD
Clodronate—Rash—Leflunomide—systemic scleroderma	0.000928	0.00173	CcSEcCtD
Clodronate—Dermatitis—Leflunomide—systemic scleroderma	0.000927	0.00173	CcSEcCtD
Clodronate—Nausea—Azathioprine—systemic scleroderma	0.000926	0.00172	CcSEcCtD
Clodronate—SLC25A4—Disease—HSPG2—systemic scleroderma	0.000924	0.00551	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—CTGF—systemic scleroderma	0.000896	0.00534	CbGpPWpGaD
Clodronate—Pruritus—Lisinopril—systemic scleroderma	0.000895	0.00167	CcSEcCtD
Clodronate—Vomiting—Mycophenolic acid—systemic scleroderma	0.000893	0.00166	CcSEcCtD
Clodronate—SLC25A4—Disease—CSK—systemic scleroderma	0.000892	0.00532	CbGpPWpGaD
Clodronate—Rash—Mycophenolic acid—systemic scleroderma	0.000885	0.00165	CcSEcCtD
Clodronate—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000884	0.00165	CcSEcCtD
Clodronate—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00088	0.00164	CcSEcCtD
Clodronate—Pharyngitis—Methotrexate—systemic scleroderma	0.000877	0.00163	CcSEcCtD
Clodronate—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000876	0.00163	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—MMP1—systemic scleroderma	0.000875	0.00522	CbGpPWpGaD
Clodronate—Nausea—Leflunomide—systemic scleroderma	0.000874	0.00163	CcSEcCtD
Clodronate—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000873	0.00162	CcSEcCtD
Clodronate—Urethral disorder—Methotrexate—systemic scleroderma	0.000866	0.00161	CcSEcCtD
Clodronate—Diarrhoea—Lisinopril—systemic scleroderma	0.000865	0.00161	CcSEcCtD
Clodronate—Anaemia—Prednisone—systemic scleroderma	0.000851	0.00158	CcSEcCtD
Clodronate—Angioedema—Prednisone—systemic scleroderma	0.000841	0.00157	CcSEcCtD
Clodronate—SLC25A4—Disease—CD247—systemic scleroderma	0.000839	0.005	CbGpPWpGaD
Clodronate—Nausea—Mycophenolic acid—systemic scleroderma	0.000834	0.00155	CcSEcCtD
Clodronate—Vomiting—Lisinopril—systemic scleroderma	0.000804	0.0015	CcSEcCtD
Clodronate—Rash—Lisinopril—systemic scleroderma	0.000797	0.00148	CcSEcCtD
Clodronate—Dermatitis—Lisinopril—systemic scleroderma	0.000797	0.00148	CcSEcCtD
Clodronate—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000796	0.00148	CcSEcCtD
Clodronate—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000784	0.00146	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000778	0.00145	CcSEcCtD
Clodronate—SLC25A4—Metabolism—HSPG2—systemic scleroderma	0.000774	0.00461	CbGpPWpGaD
Clodronate—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000758	0.00141	CcSEcCtD
Clodronate—SLC25A6—Metabolism—CTGF—systemic scleroderma	0.000751	0.00448	CbGpPWpGaD
Clodronate—Nausea—Lisinopril—systemic scleroderma	0.000751	0.0014	CcSEcCtD
Clodronate—Infection—Prednisone—systemic scleroderma	0.000746	0.00139	CcSEcCtD
Clodronate—Skin disorder—Prednisone—systemic scleroderma	0.00073	0.00136	CcSEcCtD
Clodronate—Anorexia—Prednisone—systemic scleroderma	0.000716	0.00133	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—CCL2—systemic scleroderma	0.000712	0.00424	CbGpPWpGaD
Clodronate—Anaemia—Methotrexate—systemic scleroderma	0.000711	0.00132	CcSEcCtD
Clodronate—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000705	0.00131	CcSEcCtD
Clodronate—Rash—Mycophenolate mofetil—systemic scleroderma	0.000699	0.0013	CcSEcCtD
Clodronate—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000698	0.0013	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—MMP1—systemic scleroderma	0.000683	0.00407	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism of proteins—MMP2—systemic scleroderma	0.000677	0.00404	CbGpPWpGaD
Clodronate—Dyspepsia—Prednisone—systemic scleroderma	0.000661	0.00123	CcSEcCtD
Clodronate—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000658	0.00123	CcSEcCtD
Clodronate—Decreased appetite—Prednisone—systemic scleroderma	0.000653	0.00122	CcSEcCtD
Clodronate—PTGS2—Spinal Cord Injury—IL1A—systemic scleroderma	0.000651	0.00388	CbGpPWpGaD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.00065	0.00121	CcSEcCtD
Clodronate—Infection—Methotrexate—systemic scleroderma	0.000624	0.00116	CcSEcCtD
Clodronate—Skin disorder—Methotrexate—systemic scleroderma	0.00061	0.00113	CcSEcCtD
Clodronate—Anorexia—Methotrexate—systemic scleroderma	0.000598	0.00111	CcSEcCtD
Clodronate—Urticaria—Prednisone—systemic scleroderma	0.000597	0.00111	CcSEcCtD
Clodronate—Abdominal pain—Prednisone—systemic scleroderma	0.000594	0.00111	CcSEcCtD
Clodronate—SLC25A4—Metabolism—CTGF—systemic scleroderma	0.000586	0.0035	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000566	0.00337	CbGpPWpGaD
Clodronate—Dyspnoea—Methotrexate—systemic scleroderma	0.00056	0.00104	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—CCL2—systemic scleroderma	0.000556	0.00331	CbGpPWpGaD
Clodronate—Dyspepsia—Methotrexate—systemic scleroderma	0.000553	0.00103	CcSEcCtD
Clodronate—Decreased appetite—Methotrexate—systemic scleroderma	0.000546	0.00102	CcSEcCtD
Clodronate—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000542	0.00101	CcSEcCtD
Clodronate—Pruritus—Prednisone—systemic scleroderma	0.000531	0.000989	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—MMP2—systemic scleroderma	0.000529	0.00315	CbGpPWpGaD
Clodronate—Diarrhoea—Prednisone—systemic scleroderma	0.000514	0.000957	CcSEcCtD
Clodronate—Urticaria—Methotrexate—systemic scleroderma	0.000499	0.000928	CcSEcCtD
Clodronate—Abdominal pain—Methotrexate—systemic scleroderma	0.000496	0.000924	CcSEcCtD
Clodronate—Vomiting—Prednisone—systemic scleroderma	0.000478	0.000889	CcSEcCtD
Clodronate—Rash—Prednisone—systemic scleroderma	0.000474	0.000882	CcSEcCtD
Clodronate—Dermatitis—Prednisone—systemic scleroderma	0.000473	0.000881	CcSEcCtD
Clodronate—SLC25A5—Disease—NOS3—systemic scleroderma	0.000466	0.00278	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CCL2—systemic scleroderma	0.000448	0.00267	CbGpPWpGaD
Clodronate—Nausea—Prednisone—systemic scleroderma	0.000446	0.00083	CcSEcCtD
Clodronate—Pruritus—Methotrexate—systemic scleroderma	0.000444	0.000827	CcSEcCtD
Clodronate—Diarrhoea—Methotrexate—systemic scleroderma	0.000429	0.000799	CcSEcCtD
Clodronate—PTGS2—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000429	0.00256	CbGpPWpGaD
Clodronate—Vomiting—Methotrexate—systemic scleroderma	0.000399	0.000743	CcSEcCtD
Clodronate—Rash—Methotrexate—systemic scleroderma	0.000396	0.000737	CcSEcCtD
Clodronate—Dermatitis—Methotrexate—systemic scleroderma	0.000395	0.000736	CcSEcCtD
Clodronate—SLC25A6—Disease—NOS3—systemic scleroderma	0.00039	0.00233	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—NOS3—systemic scleroderma	0.00039	0.00233	CbGpPWpGaD
Clodronate—Nausea—Methotrexate—systemic scleroderma	0.000373	0.000694	CcSEcCtD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000344	0.00205	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL1B—systemic scleroderma	0.000339	0.00202	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—NOS3—systemic scleroderma	0.000327	0.00195	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MMP9—systemic scleroderma	0.00032	0.00191	CbGpPWpGaD
Clodronate—SLC25A5—Disease—TGFB1—systemic scleroderma	0.000308	0.00184	CbGpPWpGaD
Clodronate—SLC25A4—Disease—NOS3—systemic scleroderma	0.000305	0.00182	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TGFB1—systemic scleroderma	0.000264	0.00157	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.00026	0.00155	CbGpPWpGaD
Clodronate—SLC25A6—Disease—TGFB1—systemic scleroderma	0.000258	0.00154	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—NOS3—systemic scleroderma	0.000255	0.00152	CbGpPWpGaD
Clodronate—PTGS2—Disease—SMAD7—systemic scleroderma	0.00025	0.00149	CbGpPWpGaD
Clodronate—PTGS2—Disease—TGFBI—systemic scleroderma	0.000229	0.00137	CbGpPWpGaD
Clodronate—SLC25A4—Disease—TGFB1—systemic scleroderma	0.000202	0.0012	CbGpPWpGaD
Clodronate—PTGS2—Disease—HSPG2—systemic scleroderma	0.000183	0.00109	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000179	0.00107	CbGpPWpGaD
Clodronate—PTGS2—Disease—CSK—systemic scleroderma	0.000176	0.00105	CbGpPWpGaD
Clodronate—PTGS2—Disease—CD247—systemic scleroderma	0.000166	0.000989	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—HSPG2—systemic scleroderma	0.000153	0.000912	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CTGF—systemic scleroderma	0.000116	0.000691	CbGpPWpGaD
Clodronate—PTGS2—Disease—NOS3—systemic scleroderma	6.03e-05	0.000359	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—NOS3—systemic scleroderma	5.05e-05	0.000301	CbGpPWpGaD
Clodronate—PTGS2—Disease—TGFB1—systemic scleroderma	3.98e-05	0.000237	CbGpPWpGaD
